Polaris Group
Clinical trials sponsored by Polaris Group, explained in plain language.
-
New drug combo aims to slow advanced sarcoma in phase 3 trial
Disease control Recruiting nowThis phase 3 trial tests whether adding ADI-PEG 20 to standard chemotherapy (gemcitabine and docetaxel) can help people with advanced leiomyosarcoma that has already been treated. About 300 participants will receive either the study drug or a placebo, plus chemo. The main goal is…
Phase: PHASE3 • Sponsor: Polaris Group • Aim: Disease control
Last updated May 26, 2026 08:52 UTC
-
New drug shows promise for fatty liver in early trial
Disease control Recruiting nowThis study tests a drug called ADI-PEG 20 for people with nonalcoholic steatohepatitis (NASH), a serious fatty liver disease. About 60 adults with confirmed NASH will receive either the drug or a placebo for 24 weeks. The main goal is to see if the drug reduces liver fat measured…
Phase: PHASE2 • Sponsor: Polaris Group • Aim: Disease control
Last updated May 26, 2026 08:48 UTC
-
New drug targets arginine to fight liver cancer in phase 3 trial
Disease control Recruiting nowThis study tests a drug called ADI-PEG 20 against a placebo in 300 people with advanced liver cancer that cannot be removed by surgery and who have high levels of the amino acid arginine in their blood. The goal is to see if the drug helps people live longer. Participants must ha…
Phase: PHASE3 • Sponsor: Polaris Group • Aim: Disease control
Last updated May 11, 2026 20:38 UTC